A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
- PMID: 34430373
- PMCID: PMC8350097
- DOI: 10.21037/tlcr-20-1134
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
Abstract
Objective: In this review, we aim to collect and discuss available data about the role and composition of tumor microenvironment (TME) in oligometastatic (OMD) and oligoprogressive (OPD) non-small cell lung cancer (NSCLC). Furthermore, we aim to summarize the ongoing clinical trials evaluating as exploratory objective the TME composition, through tissue and/or blood samples, in order to clarify whether TME and its components could explain, at least partially, the oligometastatic/oligoprogressive process and could unravel the existence of predictive and/or prognostic factors for local ablative therapy (LAT).
Background: OMD/OPD NSCLC represent a heterogeneous group of diseases. Several data have shown that TME plays an important role in tumor progression and therefore in treatment response. The crucial role of several types of cells and molecules such as immune cells, cytokines, integrins, protease and adhesion molecules, tumor-associated macrophages (TAMs) and mesenchymal stem cells (MSCs) has been widely established. Due to the peculiar activation of specific pathways and expression of adhesion molecules, metastatic cells seem to show a tropism for specific anatomic sites (the so-called "seed and soil" hypothesis). Based on this theory, metastases appear as a biologically driven process rather than a random release of cancer cells. Although the role and the function of TME at the time of progression in patients with NSCLC treated with tyrosine-kinase inhibitors and immune checkpoint inhibitors (ICIs) have been investigated, limited data about the role and the biological meaning of TME are available in the specific OMD/OPD setting.
Methods: Through a comprehensive PubMed and ClinicalTrials.gov search, we identified available and ongoing studies exploring the role of TME in oligometastatic/oligoprogressive NSCLC.
Conclusions: Deepening the knowledge on TME composition and function in OMD/OPD may provide innovative implications in terms of both prognosis and prediction of outcome in particular from local treatments, paving the way for future investigations of personalized approaches in both advanced and early disease settings.
Keywords: Tumor microenvironment (TME); local ablative therapy (LAT); non-small cell lung cancer (NSCLC); oligometastases; oligoprogression.
2021 Translational Lung Cancer Research. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-1134). The series “Oligometastatic NSCLC: definition and treatment opportunities” was commissioned by the editorial office without any funding or sponsorship. EB serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2021. MM reports honoraria or speakers’ fee from Pfizer, EUSA Pharma and Astra Zeneca, outside the submitted manuscript. SP reports honoraria or speakers’ fee from Astra-Zeneca, Eli-Lilly, BMS, Boehringer Ingelheim, MSD and Roche, outside the submitted manuscript. The authors have no other conflicts of interest to declare.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8350097/bin/tlcr-10-07-3369-f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8350097/bin/tlcr-10-07-3369-f2.gif)
Similar articles
-
Oligoprogression in non-small cell lung cancer: a narrative review.J Thorac Dis. 2022 Dec;14(12):4998-5011. doi: 10.21037/jtd-22-536. J Thorac Dis. 2022. PMID: 36647502 Free PMC article. Review.
-
Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.J Thorac Oncol. 2017 Feb;12(2):179-193. doi: 10.1016/j.jtho.2016.10.012. Epub 2016 Oct 22. J Thorac Oncol. 2017. PMID: 27780780 Review.
-
Local control strategies for management of NSCLC with oligoprogressive disease.Cancer Treat Rev. 2023 Nov;120:102621. doi: 10.1016/j.ctrv.2023.102621. Epub 2023 Sep 2. Cancer Treat Rev. 2023. PMID: 37690180 Review.
-
Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.Ther Adv Med Oncol. 2023 Mar 4;15:17588359231156387. doi: 10.1177/17588359231156387. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895853 Free PMC article.
-
Oligoprogression in Non-Small Cell Lung Cancer.Cancers (Basel). 2021 Nov 20;13(22):5823. doi: 10.3390/cancers13225823. Cancers (Basel). 2021. PMID: 34830977 Free PMC article. Review.
Cited by
-
KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype.Int J Mol Sci. 2024 Mar 20;25(6):3510. doi: 10.3390/ijms25063510. Int J Mol Sci. 2024. PMID: 38542481 Free PMC article.
-
Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies.Curr Oncol Rep. 2024 Jan;26(1):80-89. doi: 10.1007/s11912-023-01490-6. Epub 2024 Jan 2. Curr Oncol Rep. 2024. PMID: 38175464 Review.
-
CD47 Expression in Circulating Tumor Cells and Circulating Tumor Microemboli from Non-Small Cell Lung Cancer Patients Is a Poor Prognosis Factor.Int J Mol Sci. 2023 Jul 26;24(15):11958. doi: 10.3390/ijms241511958. Int J Mol Sci. 2023. PMID: 37569332 Free PMC article.
-
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer.Front Pharmacol. 2023 Mar 24;14:1130937. doi: 10.3389/fphar.2023.1130937. eCollection 2023. Front Pharmacol. 2023. PMID: 37033636 Free PMC article. Review.
-
Oligoprogression in non-small cell lung cancer: a narrative review.J Thorac Dis. 2022 Dec;14(12):4998-5011. doi: 10.21037/jtd-22-536. J Thorac Dis. 2022. PMID: 36647502 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials